Bridging therapy after recent stent implantation: case report and review of data.

Cardiovasc Revasc Med

Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Published: October 2012

For patients requiring surgery within their first year following coronary stent placement, maximizing the prevention of stent thrombosis with antiplatelet therapy while minimizing the risk of intraoperative bleeding has become a management challenge for cardiologists, surgeons and anesthesiologists. In this manuscript, we describe a case of a patient who received three stents (two of which were drug-eluting) and 7 months later was bridged with intravenous eptifibatide, a short-acting glycoprotein (GP) IIb/IIIa inhibitor, for 3 days prior to bronchoscopy and cervical mediastinoscopy for a suspected lung cancer. We then review the current literature for data and guidelines describing the use of short-acting GP IIb/IIIa as bridge therapy. Finally, we provide recommendations, based on our experience combined with this review, for bridge therapy in the perioperative period for patients with recent coronary stents.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.carrev.2011.08.004DOI Listing

Publication Analysis

Top Keywords

bridge therapy
8
bridging therapy
4
therapy stent
4
stent implantation
4
implantation case
4
case report
4
report review
4
review data
4
data patients
4
patients requiring
4

Similar Publications

Introduction: Bisphosphonates are commonly used to prevent osteoporotic fractures. Many randomized controlled trials have proved the efficacy of bisphosphonates, showing their ability to increase bone mineral density and decrease the risk of hip and vertebral fractures. Atypical, bisphosphonate-related fractures concerning the femur have been widely described and a list of primary and secondary clinical and radiographic criteria are used in order to achieve diagnosis.

View Article and Find Full Text PDF

Hepatocellular cancer (HCC) therapy is in need for an ideal companion diagnostic. Preclinical experimental studies have identified the insulin receptor (IR) and its synergistic counterpart, the IGF1 receptor (IGF1R), as relevant in HCC development, and the ligands IGF1 and IGF2 have been found to be elevated in HCC. This study aimed to bridge the gap to the clinical setting and explore whether the IR or the IGF1R would be of prognostic significance and would be associated with clinicopathologic parameters in HCC patients.

View Article and Find Full Text PDF

Background: Small Bowel Adenocarcinoma (SBA) is a rare gastrointestinal cancer with a limited understanding of the molecular pathology. This study aims to bridge the knowledge gap, providing a robust molecular foundation for SBA and addressing the clinical challenges inherent in treating this orphan disease. The study proposes to redefine the clinical management for SBA patients through advanced molecular profiling techniques to improve potential precision medicine.

View Article and Find Full Text PDF

Tröger's Base as a Potential Bridge to Type-I Photosensitizers: Mechanism and Antitumor Applications.

J Med Chem

January 2025

School of Chemistry and Materials Science, Jiangsu Normal University, No. 101 Shanghai Road, 221116 Xuzhou, China.

In contrast to Type-II photodynamic therapy (PDT), Type-I PDT with less oxygen consumption has shown great potential against tumor hypoxia. However, there are limited strategies available for designing Type-I photosensitizers (PSs). Herein, we present a promising strategy for synthesizing Type-I PSs () using Tröger's base (TB) framework.

View Article and Find Full Text PDF

Sudden cardiac death (SCD) remains a major global health concern and represents one of the most common causes of mortality due to cardiovascular diseases. The wearable cardioverter-defibrillator (WCD) is an innovative, non-invasive medical device designed to provide continuous heart monitoring and immediate defibrillation in patients at risk for SCD. The study aimed to assess the efficacy of WCD usage in patients awaiting decision on therapy with implantable cardioverter-defibrillators (ICDs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!